Inflammatory bowel diseases (IBD) are characterized by chronic inflammation of the
intestinal tract associated with an imbalance of the intestinal microbiota. Crohn's disease …

Biosimilars, based on biopharmaceuticals approved by regulatory agencies that are no
longer under patent protection, have efficacy and safety comparable to their reference …

Despite the establishment of a specific approval pathway, the issuance of detailed scientific
guidelines for the development of similar biological medicinal products (so-called …

The study aimed to develop evidence-based recommendations regarding the evaluation
and use of biosimilars to treat rheumatological diseases. The task force comprised an expert …

Many of the best-selling 'blockbuster'biological medicinal products are, or will soon be,
facing competition from similar biological medicinal products (biosimilars) in the EU …

Abstract Background and Aim The biosimilar of infliximab, CT‐P13, has recently been
shown to be equivalent to infliximab in both efficacy and safety in the treatment of …

Introduction: While prescribing biosimilars to patients naive to a biologic treatment is a well-
accepted practice, switching clinically stable patients from an originator to a biosimilar is an …

Background Anti‐tumour necrosis factor (anti‐TNF) monoclonal antibodies have shown
efficacy in inflammatory bowel diseases (IBD). As these therapies lose patent protection …

Biologic therapies have changed the outcome of both adult and pediatric patients with
Inflammatory Bowel Disease (IBD). In September 2013, the first biosimilar of infliximab was …

Background Clinicians are required to assimilate, critically evaluate, and extrapolate
information to support appropriate use of biosimilars across indications. Objectives The …